Global Biologics Market Briefing 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Biologics Market Global Briefing 2018" report has been added to ResearchAndMarkets.com's offering.

Biologics Market Global Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global biologics sector.

The biologics industry comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.

North America was the largest region in the biologics market in 2017, accounting for around 40% market share. This can be attributed to the high per capita healthcare expenditure in the region and the investment in novel treatments leading to the early adoption of new anti-inflammatory, anti-cancer and anti-viral biologics in the region. Western Europe was the second largest region accounting for around 23% market share. Asia Pacific was the third largest region accounting for around 16% market share.

Demand for Biologics in The Treatment of Complex Diseases - Biologics are being widely used to provide effective treatment for many complex diseases such as rheumatoid arthritis, psoriasis, Crohn's disease that have limited treatment options. There has been a significant advancement for the treatment of Rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of Rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan).

Key biologics used to treat psoriasis include Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Secukinumab ( Cosentyx). Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab), Tysabri (natalizumab) are biologics that are used to treat Crohn's disease.

Scope:

  • Markets Covered: Therapeutic Proteins, Monoclonal Antibodies (MAbS), Vaccines.
  • Companies Mentioned: Amgen, AbbVie, Johnson & Johnson, Bristol-Myers Squibb Company, Pfizer, Eli Lilly, F. Hoffmann-La Roche Ltd, Merck & Co., GlaxosmithKline, Novo Nordisk
  • Time Series: Five years historic and forecast.
  • Data: Market value in $ billions.
  • Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

For more information about this report visit https://www.researchandmarkets.com/research/6tjxrl/global_biologics?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biopharmaceuticals

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biopharmaceuticals